acetaminophen / COX2 Cancer Research Results

acet, acetaminophen: Click to Expand ⟱
Features:

Acetaminophen — Acetaminophen (also called paracetamol; common abbreviation APAP) is a small-molecule analgesic and antipyretic used for pain and fever. It is a non-opioid, non-NSAID analgesic with weak peripheral anti-inflammatory activity compared with NSAIDs, and its clinically relevant actions are largely central (CNS) rather than peripheral. It is widely available OTC and in many combination products; overdose risk is driven by total aggregate APAP exposure across products.

Primary mechanisms (ranked):

  1. Central prostaglandin synthesis suppression via inhibition of prostaglandin H synthase (COX peroxidase site) under low-peroxide conditions → ↓PGE2 signaling (analgesic/antipyretic dominant)
  2. Central neuromodulation (context-dependent): serotonergic descending inhibitory pathways and endocannabinoid-related signaling (including AM404 formation) contributing to analgesia
  3. Thermoregulatory set-point effects in hypothalamus downstream of ↓PGE2 (antipyresis)
  4. High-dose/toxicity mechanism: CYP-mediated bioactivation → NAPQI formation → glutathione depletion, mitochondrial oxidative stress and hepatocellular injury

Bioavailability / PK relevance: Oral acetaminophen is generally well absorbed; therapeutic plasma half-life is typically ~1.5–3 hours in adults, with hepatic clearance dominated by glucuronidation and sulfation; a smaller fraction undergoes CYP oxidation to NAPQI. Hepatotoxic risk increases when detox capacity (glutathione) is compromised or when oxidative bioactivation is increased.

In-vitro vs systemic exposure relevance: Therapeutic effects are not typically driven by high cytotoxic concentrations; many cell-culture toxicity phenotypes reflect supratherapeutic exposure and/or bioactivation contexts not representative of normal systemic dosing.

Clinical evidence status: Established standard-of-care symptomatic therapy (OTC and prescription formulations) for pain and fever; major safety signal is dose-dependent hepatotoxicity from overdose and unintentional “stacking” across combination products.


Pathways:
-Cytochrome P450 Metabolism: NAPQI (N-acetyl-p-benzoquinone imine)
-Excess NAPQI depletes glutathione, a key antioxidant. The absence of sufficient glutathione leads to elevated oxidative stress.
-NF-κB Activation:
-Direct DNA Damage:

Excess results in increased oxidative stress, mitochondrial dysfunction, and ultimately hepatocellular damage (liver injury)

Mechanistic axes relevant to acetaminophen (therapeutic action and dose-limiting toxicity)

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Central prostaglandin synthesis ↔ (not a primary anticancer mechanism) ↓ PGE2 signaling in CNS P–R Analgesia, antipyresis Clinically consistent with central COX/PGHS functional inhibition (peroxidase-site, redox-state dependent) with minimal peripheral anti-inflammatory effect vs NSAIDs.
2 Serotonergic descending pain inhibition ↔ ↑ descending inhibitory tone (context-dependent) P–R Analgesia Frequently described as contributory; magnitude varies by model and co-administered agents.
3 Endocannabinoid-related signaling and TRPV1 (AM404 axis) ↔ ↑ cannabinoid/TRPV1-linked modulation (context-dependent) R Analgesia (adjunctive) AM404 is a CNS metabolite implicated in some mechanistic models; relevance varies across species and experimental systems.
4 ROS and mitochondrial oxidative stress (toxicity axis) ↑ (high concentration only) ↑ (overdose context) R–G Hepatocellular injury Overdose: NAPQI formation + GSH depletion → mitochondrial dysfunction and oxidative stress; this is dose-limiting and not a therapeutic mechanism.
5 NRF2 and glutathione homeostasis (toxicity modifier) ↔ (context-dependent) ↑ adaptive response; ↓ GSH predisposes to injury G Determines resilience to NAPQI Risk is increased when baseline GSH is low (e.g., fasting/starvation) or when metabolism shifts toward oxidation pathways.
6 Clinical Translation Constraint — — — Dose ceiling due to hepatotoxicity risk Major real-world risk is inadvertent overdose from multi-product use; labeling emphasizes total daily maximum across all sources/routes.


COX2, cycloocygenase-2 (Cox-2) mRNA and Cox-2 protein: Click to Expand ⟱
Source: HalifaxProj(inhibit)
Type:
Cyclooxygenase-2 (COX-2) is an enzyme that plays a critical role in the conversion of arachidonic acid to prostaglandins, which are lipid compounds involved in various physiological processes, including inflammation, pain, and fever. COX-2 is an inducible enzyme, meaning its expression is typically low in normal tissues but can be upregulated in response to inflammatory stimuli, growth factors, and certain oncogenic signals.
-Cyclooxygenase-2 (COX-2), the rate-limiting enzyme in prostaglandin biosynthesis, plays a key role in inflammation and circulatory homeostasis.
-COX-2 is an inducible enzyme that is upregulated in response to pro-inflammatory signals, including cytokines (e.g., IL-1β, TNF-α) and growth factors.

COX-2 is often overexpressed in various tumors, including colorectal, breast, lung, and prostate cancers.
The prostaglandins produced by COX-2, particularly prostaglandin E2 (PGE2), have several effects that can facilitate cancer progression:
Cell Proliferation: PGE2 can promote the proliferation of cancer cells by activating signaling pathways such as the PI3K/Akt and MAPK pathways.
Nonselective NSAIDs, such as aspirin and ibuprofen, inhibit both COX-1 and COX-2. Epidemiological studies have suggested that regular use of NSAIDs may reduce the risk of certain cancers, particularly colorectal cancer.
Drugs specifically targeting COX-2, such as celecoxib, have been developed.

COX-2 and xanthine oxidase are ROS-producing pro-oxidant enzymes that contribute to inflammation. Elevated COX‑2 levels, often found in inflammatory conditions or certain types of cancers, can contribute to increased production of ROS.
Scientific Papers found: Click to Expand⟱
5313- acet,    Pharmacological hypotheses: Is acetaminophen selective in its cyclooxygenase inhibition?
- Review, Nor, NA
*COX2↓,
1478- SFN,  acet,    Anti-inflammatory and anti-oxidant effects of combination between sulforaphane and acetaminophen in LPS-stimulated RAW 264.7 macrophage cells
- in-vitro, Nor, NA
eff↑, NO↓, iNOS↓, COX2↓, IL1β↓, ROS↓,

Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

ROS↓, 1,  

Cell Death ⓘ

iNOS↓, 1,  

Angiogenesis & Vasculature ⓘ

NO↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 1,   IL1β↓, 1,  

Drug Metabolism & Resistance ⓘ

eff↑, 1,  
Total Targets: 6

Pathway results for Effect on Normal Cells:


Immune & Inflammatory Signaling ⓘ

COX2↓, 1,  
Total Targets: 1

Scientific Paper Hit Count for: COX2, cycloocygenase-2 (Cox-2) mRNA and Cox-2 protein
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:275  Target#:66  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page